01/09/2023
PrognomiQ’s Multi-omics Liquid Biopsy Platform Demonstrates Promising Results in Early-Stage Cancer Detection of Non-Small Cell Lung Cancer
Read More
11/29/2022
PrognomiQ Strengthens its Scientific and Clinical Leadership with the Appointment of Brian Koh, M.D. as Chief Medical Officer
Read More
06/21/2022
Maccabi’s KSM Research and Innovation Center & PrognomiQ Announce Research Collaboration Aimed at Early Cancer Detection
Read More
03/15/2022
PrognomiQ Announces $46 Million Financing to Advance Development of its Multi-omics Product Pipeline for Early Detection and Treatment of Cancer
Read MoreThe news articles below were developed independently and any commentary or opinions are those of the publication.
September 2022
High-Dimensional, Multi-Omics Analyses of Proteins, Metabolites, Transcripts, and Genes Enable Biomarker Discovery in Early- and…
See Poster
June 2022
Combining Proteograph technology with Zeno SWATH acquisition enables the potential for deep, unbiased discovery of…
See Poster
June 2022
An unbiased multi-omics approach for the detection of pancreatic cancer biomarkers utilizing ion-mobility mass spectrometry…
See Poster
April 2022
Deep, unbiased multi-omics approach for identification of pancreatic cancer biomarkers from blood
See Poster
March 2022
Incorporation of glycoproteome detection into large scale unbiased proteomics studies utilizing nanoparticles
See Poster
November 2021
Large scale, deep, and unbiased proteomics profiling a sub-study of a multi-cancer cohort enabling biomarker…
See Poster
